| AUTL |
Autolus Therapeutics plc |
80%
|
Reciprocal relationship from AUTL graph: As the Product Options within the BioNTech License and Option Agreement were an embedded feature within a freestanding financial instrument, the Company asses… |
| AUTL |
Autolus Therapeutics plc |
72%
|
1,254.0 9,739.6 92.7 11.9 41.1 9,739.6 Cash and cash equivalents Cash at banks and on hand Yes AC 450.0 — 450.0 — — — 450.0 Money market funds Yes FVTPL 6,947.5 — 6,947.5 6,947.5 — — 6,947.5 Deposits… |
| EVAX |
Evaxion A/S |
72%
|
Reciprocal relationship from EVAX graph: ing income in the mid double-digit range. We have initiated a Phase 2 trial, hence this term is no longer relevant. Prior to any out-licensing commercializati… |
| MGNX |
MacroGenics, Inc. |
72%
|
Reciprocal relationship from MGNX graph: t and future product candidates. Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we o… |
| MTNB |
Matinas BioPharma Holdings, Inc. |
72%
|
Reciprocal relationship from MTNB graph: contractors associated with Chemistry and Manufacturing Controls (CMC), pre-clinical and clinical activities and regulatory operations; ● expenses incurred un… |
| ROIV |
Roivant Sciences Ltd. |
72%
|
Reciprocal relationship from ROIV graph: y need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates following regulatory approval, and w… |
| SMMT |
Summit Therapeutics Inc. |
72%
|
Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”).… |
| APA-CUREVAC-AG |
APA-CUREVAC-AG |
62%
|
rations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition, joint venture or collaboration may entail numero… |
| ARBUTUS-BIOPHARMA-CORP |
ARBUTUS-BIOPHARMA-CORP |
62%
|
orm 20-F for the year ended December 31, 2025 Table of Contents – delays to the development timelines for our product candidates; – interruption of supply resulting from modifications to or discontin… |
| BAYER-CROPSCIENCE-LLC |
BAYER-CROPSCIENCE-LLC |
62%
|
orm 20-F for the year ended December 31, 2025 Table of Contents – delays to the development timelines for our product candidates; – interruption of supply resulting from modifications to or discontin… |
| BAYER-MONSANTO-COMPANY |
BAYER-MONSANTO-COMPANY |
62%
|
orm 20-F for the year ended December 31, 2025 Table of Contents – delays to the development timelines for our product candidates; – interruption of supply resulting from modifications to or discontin… |
| BIPARTISAN-SENATE-AI-WORKING-GROUP |
BIPARTISAN-SENATE-AI-WORKING-GROUP |
62%
|
or precision medicine (e.g., clinical decision support), for supporting clinical trial design or assessing patient eligibility for clinical trials, for drafting medicinal product information document… |
| BMY |
Bristol-Myers Squibb Company |
62%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from BMY graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from BMY grap… |
| BRISTOL-MYERS-SQUIBB-COMPANY |
BRISTOL-MYERS-SQUIBB-COMPANY |
62%
|
. During the year ended December 31, 2025 , revenues in the amount of € 613.0 million were recognized on a cumulative catch-up basis as of June 2, 2025, the date the initial agreement was effective, … |
| CUREVAC-AG |
CUREVAC-AG |
62%
|
rations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition, joint venture or collaboration may entail numero… |
| CUREVAC-CUREVAC-AG |
CUREVAC-CUREVAC-AG |
62%
|
rations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition, joint venture or collaboration may entail numero… |
| DUALTIY-BIOLOGICS-CO-LTD |
DUALTIY-BIOLOGICS-CO-LTD |
62%
|
1,254.0 9,739.6 92.7 11.9 41.1 9,739.6 Cash and cash equivalents Cash at banks and on hand Yes AC 450.0 — 450.0 — — — 450.0 Money market funds Yes FVTPL 6,947.5 — 6,947.5 6,947.5 — — 6,947.5 Deposits… |
| EY-GMBH |
EY-GMBH |
62%
|
ted probabilities of successful development and revenue projections by comparing them to observable industry and economic trends and standards, external data sources, and historical product trends, i… |
| F-2-EY-GMBH |
F-2-EY-GMBH |
62%
|
any evaluation of the effectiveness of internal control over financial reporting into future periods are subject to inherent risk. The relevant controls may become inadequate due to changes in circum… |
| GENEVANT-SCIENCES-GMBH |
GENEVANT-SCIENCES-GMBH |
62%
|
orm 20-F for the year ended December 31, 2025 Table of Contents – delays to the development timelines for our product candidates; – interruption of supply resulting from modifications to or discontin… |
| GERMAN-STOCK-CORPORATION |
GERMAN-STOCK-CORPORATION |
62%
|
unless otherwise required by law, our Articles of Association or the rules of procedure of our Supervisory Board. In the event of a tie, the chairperson of the Supervisory Board has the casting vote.… |
| GLAXOSMITHKLINE-LLC |
GLAXOSMITHKLINE-LLC |
62%
|
orm 20-F for the year ended December 31, 2025 Table of Contents – delays to the development timelines for our product candidates; – interruption of supply resulting from modifications to or discontin… |
| GSK |
GSK plc |
62%
|
Reciprocal relationship from GSK graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from GSK graph: Reciprocal relationship from BNTX graph: orm 20-F for the year ended December … |
| INSTADEEP-LTD |
INSTADEEP-LTD |
62%
|
to identify, recruit and retain key personnel; – our and our collaborators’ ability to protect and enforce our intellectual property protection for our proprietary and collaborative product candidate… |
| KPMG-AG |
KPMG-AG |
62%
|
020 where she led on life sciences, NHS data and digital transformation and global health security. Among other roles, she was Chair of the technical regulator, the Human Tissue Authority, as well as… |
| MEDILINK-THERAPEUTICS-CO-LTD |
MEDILINK-THERAPEUTICS-CO-LTD |
62%
|
as securities for liabilities. During the years ended December 31, 2025 and 2024 , inventories in the amount of € 189.3 million and € 129.5 million , respectively, were recognized as cost of sales. F… |
| MIG-VERWALTUNGS-AG |
MIG-VERWALTUNGS-AG |
62%
|
020 where she led on life sciences, NHS data and digital transformation and global health security. Among other roles, she was Chair of the technical regulator, the Human Tissue Authority, as well as… |
| MONSANTO-TECHNOLOGY-LLC |
MONSANTO-TECHNOLOGY-LLC |
62%
|
orm 20-F for the year ended December 31, 2025 Table of Contents – delays to the development timelines for our product candidates; – interruption of supply resulting from modifications to or discontin… |
| WACKER-CHEMIE-AG |
WACKER-CHEMIE-AG |
62%
|
020 where she led on life sciences, NHS data and digital transformation and global health security. Among other roles, she was Chair of the technical regulator, the Human Tissue Authority, as well as… |
| WACKER-SILTRONIC-CORPORATION |
WACKER-SILTRONIC-CORPORATION |
62%
|
020 where she led on life sciences, NHS data and digital transformation and global health security. Among other roles, she was Chair of the technical regulator, the Human Tissue Authority, as well as… |
